featured
Short-Course, Direct-Acting Antivirals and Ezetimibe to Prevent HCV Infection in Recipients of Organs From HCV-Infected Donors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Gastroenterology & Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Short-Course, Direct-Acting Antivirals and Ezetimibe to Prevent HCV Infection in Recipients of Organs From HCV-Infected Donors: A Phase 3, Single-Centre, Open-Label Study
Lancet Gastroenterol Hepatol 2020 May 06;[EPub Ahead of Print], JJ Feld, M Cypel, D Kumar, H Dahari, RV Pinto Ribeiro, N Marks, N Kamkar, I Bahinskaya, FQ Onofrio, MA Zahoor, O Cerrochi, K Tinckam, SJ Kim, J Schiff, TW Reichman, M McDonald, C Alba, TK Waddell, G Sapisochin, M Selzner, S Keshavjee, HLA Janssen, BE Hansen, LG Singer, A HumarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.